Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter
fghjkjhb

Evidence gap analysis

Strategic analysis of the sufficiency of evidence to obtain reimbursement and HTA approval in Europe and recommendations about evidence generation

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Recent news and posts

Tags

Use tags to find relevant records
3D printed implants
Ablation methods
Allogeneic mesenchymal stem cells
Ambulatory ECG monitoring
Aortic abdominal aneurysm
Aortic root replacement
Arthroplasty
Arthroscopy
Assisted ventilation
Atherectomy
Austria
Autologous chondrocyte implantation
Automated external defibrillator
AV fistula
AV graft
Balloon kyphoplasty
Bariatric surgery
Baroreflex activation therapy
Barrett’s oesophagus
Belgium
Benign prostatic hyperplasia
Biopsy
Bone Conductive Hearing Device
Breast reconstruction
Bronchial thermoplasty
Burns
Caesarean section
Cancer
Capsule endoscopy
Carbon ion therapy
Cardiac ablation
Cardiac computer tomography
Cardiac pacemaker
Cardiac resynchronization therapy
Cardiac Resynchronization Therapy Defibrillator (CRT-D)
Cardiovascular devices
Cardiovascular procedures
Carotid endarterectomy
Cataract
Cell therapy
Cholecystectomy
Chronic obstructive pulmonary disease
Chronic wounds
Clinical guidelines
Cochlear implants
Commissioning
Computed tomography
Conditional reimbursement
Connected medical devices
Continuous glucose monitoring (CGM)
Coronary interventions
Coronary percutaneous revascularization procedures
Coronary procedures
Coronavirus
Coverage with evidence development (CED)
Critical care
See all tags

Newborn screening for hereditary tyrosinaemia type 1 introduced in England

Hereditary tyrosinaemia type 1 (HT1) is a very rare genetic condition affecting about seven babies per year in the UK. It prevents the body from breaking down a substance called tyrosine found in food. This leads to the build-up of toxic levels of substances in the blood that can damage the liver, kidneys, and nervous system.

UK National Screening Committee carried out the review in 2022 and recommended screening for HT1. 

In March 2024, the English government endorsed the UK National Screening Committee's recommendation to introduce newborn screening for HT1. Testing for HT1 will be added to the NHS Newborn Blood Spot Screening Programme in England.

See more details here and here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.

Tags
In-vitro diagnostic tests
UK

The latest related news

26
Apr 2024

2024/25 Prescribed Specialised Services Operational Tool released in England

On April 3, 2024, NHS England published the 2024/25 Prescribed Specialised Services (PSS) Operational Tool. This Tool is used as a mechanism to identify whether healthcare activity belongs to specialized services using so-called identification rules. Forty-three new service lines were introduced in multiple areas, and eight service lines were amended.
Read more
25
Apr 2024

Published HTAs in Q1 2024 in Scotland

In Scotland, the Scottish Health Technology Group (SHTG) develops HTAs and clinical guidelines to support decision-making. The assessments on artificial intelligence supported clinician review of chest X-rays from patients with suspected lung cancer; an assessment of local anesthetic biopsies of suspicious laryngeal and pharyngeal lesions; a digital prevention program for people at risk of Type 2 diabetes were published in the first quarter of 2024.
Read more
23
Apr 2024

Med Tech-related technology assessments and clinical guidelines from NICE in March 2024

In March 2024, the National Institute for Health and Care Excellence (NICE) published two new Health Technology Evaluations using early value assessment (digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people, and digital technologies for managing non-specific low back pain). Furthermore, three new clinical guidelines were published, four clinical guidelines, and two Health Technology Evaluations were updated.
Read more
22
Apr 2024

Decree relating to the RIHN framework reform published in France

On March 31, 2024, the Ministry of Labor, Health, and Solidarity published a Decree in the Official Journal of the French Republic relating to the conditions of coverage of innovative IVD tests within the RIHN framework, which should facilitate the transition from the RIHN framework to regular reimbursement via the NABM Nomenclature.
Read more
19
Apr 2024

Med Tech-related health technology assessments from NIHR in March 2024

In March 2024, the National Institute for Health and Care Research (NIHR) in England released four MedTech-related assessments in its Health Technology Assessment (HTA) Journal, which concerned septoplasty in deviated nasal septum, software with AI-derived algorithms for analyzing CT brain scans, KardiaMobile 6L for measuring QT interval, and surgical management of pelvic fractures. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs National Institute for Health and Care Excellence (NICE) guidance.
Read more